copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
KaliVir Immunotherapeutics Announces FDA Clearance of Investigational . . . PITTSBURGH, PA (July 1, 2024) – KaliVir Immunotherapeutics, Inc , a biotech company developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs, today announced that the FDA has cleared the Investigational New Drug (IND) application for the STEALTH-001 study of VET3-TGI in patients with incurable, advanced solid tumors
KaliVir Immunotherapeutics Announces FDA Clearance of IND for Oncolytic . . . The Phase 1 1b study (ClinicalTrials gov ID NCT06444815) will evaluate the safety profile and efficacy of VET3-TGI when administered through intravenous infusion or intratumoral injection in patients with advanced, incurable solid tumors The trial will assess VET3-TGI both as a monotherapy and in combination with checkpoint inhibitor therapy
Abstract CT122: Trial in progress: Phase 1 study of an oncolytic virus . . . AbstractBackground: Conventional therapies still have limited curative efficacy for many advanced solid tumors, prompting research into immunotherapies including oncolytic viruses ASP1012, a double-stranded DNA oncolytic and immunotherapeutic vaccinia virus encoding a leptin-interleukin 2 fusion protein that selectively replicates in cancer cells, is being developed for the treatment of
KaliVir Immunotherapeutics Announces FDA Clearance of . . . - BioSpace KaliVir Immunotherapeutics, Inc , a biotech company developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs, announced clearance of an Investigational New Drug application by the United States Food and Drug Administration to initiate a Phase 1 clinical study of ASP1012 in participants with locally advanced or metastatic solid tumors
KaliVir announces US FDA clears IND application to initiate phase 1 . . . Discovered and developed by Kalivir and licensed to Astellas Pharma Inc in December 2020, ASP1012 (formerly named VET2-L2) is a systemic oncolytic vaccinia virus therapy in which the virus is delivered intravenously and expresses Leptin-IL2 fusion protein as a therapeutic payload The trial is expected to begin in Q1 2024
FDA clears IND for systemic oncolytic vaccinia virus therapy . . . - BioWorld Kalivir Immunotherapeutics Inc has announced FDA clearance of an IND application for a phase I study of ASP-1012 (formerly VET2-L2) in participants with locally advanced or metastatic solid tumors The trial is expected to begin in the first quarter of next year
KaliVir Immunotherapeutics Gets FDA Clearance for Oncolytic . . . KaliVir Immunotherapeutics, Inc , a biotechnology company specializing in advanced oncolytic viral immunotherapy, has announced that the United States Food and Drug Administration (FDA) has approved their Investigational New Drug (IND) application for the STEALTH -001 study This study will investigate the therapeutic potential of VET3-TGI in patients suffering from advanced, incurable solid
NEWS - KaliVir Immunotherapeutics KaliVir Immunotherapeutics Announces Pre-Clinical Data for Oncolytic Therapy VET3-TGI at the Society for Immunology of Cancer (SITC) 37th Annual Meeting
VET2-L2 - Drug Targets, Indications, Patents - Synapse A Phase 1, Open-Label, Dose Escalation and Expansion Study of ASP1012, an Oncolytic Virus, in Participants With Locally Advanced or Metastatic Solid Tumors ASP1012 is a type of virus called an oncolytic virus which is used to treat some cancers ASP1012 was changed in a laboratory to infect and kill cancer cells, leaving healthy cells alone
KaliVir Immunotherapeutics Announces FDA Clearance of Investigational . . . Discovered and developed by Kalivir and licensed to Astellas Pharma Inc in December 2020, ASP1012 (formerly named VET2-L2) is a systemic oncolytic vaccinia virus therapy in which the virus is delivered intravenously and expresses Leptin-IL2 fusion protein as a therapeutic payload The trial is expected to begin in Q1 2024